-- ジェフリーズが木曜日に発表したレポートによると、HUB24(ASX:HUB)の純資金流入額は約40億豪ドルで、直近のトレンドを下回った。7四半期移動平均は約51億豪ドルとなっている。 同社は火曜日、3月31日時点の運用資産総額が1,517億4,000万豪ドルとなり、前年同期の1,241億3,000万豪ドルから22%増加したと発表した。 投資会社は、この業績発表に対する株価の反応は「厳しい」ものの、2027年度予想PERが46倍で取引されている現状では、株価が期待外れにならないのは難しいと指摘した。 ジェフリーズは、ネットウェルス・グループ(ASX:NWL)とジェネレーション・デベロップメント・グループ(ASX:GDG)に割安感があると見ており、両社の過去3年間の株価収益率(PER)成長率はそれぞれ約2倍と1.26倍である一方、2027年度予想PERと比較して大幅なディスカウントで取引されていると指摘した。 ジェフリーズはHub24の投資判断を「ホールド」に据え置き、目標株価を93.50豪ドルから94豪ドルに引き上げた。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.